CAS 1194506-26-7

Fruquintinib

Description:

Fruquintinib is a small molecule drug primarily used in the treatment of certain types of cancer, particularly colorectal cancer. It functions as a selective inhibitor of vascular endothelial growth factor receptors (VEGFR), which play a crucial role in tumor angiogenesis—the process by which tumors develop their own blood supply. By inhibiting these receptors, Fruquintinib effectively restricts tumor growth and metastasis. The compound is characterized by its oral bioavailability, allowing for convenient administration. Its chemical structure includes specific functional groups that contribute to its activity and selectivity. Fruquintinib has undergone various clinical trials to evaluate its efficacy and safety profile, demonstrating promising results in improving patient outcomes. As with many targeted therapies, potential side effects may include hypertension, fatigue, and gastrointestinal disturbances, necessitating careful monitoring during treatment. Overall, Fruquintinib represents a significant advancement in targeted cancer therapy, offering a novel approach to managing malignancies through the inhibition of angiogenic pathways.

Formula: C₂₁H₁₉N₃O₅

Synonyms:

• 6-(6,7-dimethoxyquinazolin-4-yloxy)-N,2-dimethylbenzofuran-3-carboxamide
• 3-Benzofurancarboxamide, 6-[(6,7-dimethoxy-4-quinazolinyl)oxy]-N,2-dimethyl-
• 6-[(6,7-Dimethoxy-4-quinazolinyl)oxy]-N,2-dimethyl-3-benzofurancarboxamide
• EOS-61054
• CS-1643
• R-228060
• 6-[(6,7-Dimethoxy-4-quinazolinyl)oxy]-N,2-dimethyl-1-benzofuran-3-carboxamide
• Fruquintinib
• HMPL-013
• Fruquintinib|HMPL-013
• Fruquintinib|HMPL-013 USP/EP/BP

6-[(6,7-Dimethoxy-4-quinazolinyl)oxy]-N,2-dimethyl-3-benzofurancarboxamide

CAS: 1194506-26-7

Formula: C₂₁H₁₉N₃O₅

Purity: 98%

Color and Shape: Solid

Molecular weight: 393.3927

Ref: IN-DA003ATK

Fruquintinib

CAS: 1194506-26-7

Formula: C₂₁H₁₉N₃O₅

Molecular weight: 393.40

Ref: 4Z-F-237001

Fruquintinib

CAS: 1194506-26-7

Fruquintinib

Purity: ≥98%

Molecular weight: 393.39g/mol

Ref: 54-BUP10066

6-((6,7-Dimethoxyquinazolin-4-Yl)Oxy)-N,2-Dimethylbenzofuran-3-Carboxamide

CAS: 1194506-26-7

6-((6,7-Dimethoxyquinazolin-4-Yl)Oxy)-N,2-Dimethylbenzofuran-3-Carboxamide

Purity: 98%

Molecular weight: 393.39g/mol

Ref: 54-OR1026272

Fruquintinib

CAS: 1194506-26-7

Fruquintinib (HMPL-013) is an orally available, small molecule inhibitor of vascular endothelial growth factor receptors (VEGFRs), with potential anti-

Formula: C₂₁H₁₉N₃O₅

Purity: 98.84% - 99.89%

Color and Shape: Solid

Molecular weight: 393.39

Ref: TM-T2656

Fruquintinib

CAS: 1194506-26-7

Purity: 98%

Molecular weight: 393.398986816406

Ref: 10-F826282

Fruquintinib

CAS: 1194506-26-7

Fruquintinib is an investigational drug that targets the cell signaling pathways involved in the progression of metastatic colorectal cancer and leukemia. It has been shown to inhibit the body's production of malonic acid, which is a precursor in the synthesis of collagen. Fruquintinib also inhibits choroidal neovascularization, a condition that can lead to blindness. The drug has been evaluated as a treatment option for renal cell cancer and malignant melanoma, with promising results. Fruquintinib binds to proteins in the blood and reaches its highest concentrations in plasma after one hour. The drug does not bind well to proteins in the gastrointestinal tract, which means that it is only minimally absorbed from this site of administration. Fruquintinib is metabolized extensively by cytochrome P450 enzymes and glucuronidases (UGTs) into metabolites that are excreted via urine and bile.

Formula: C₂₁H₁₉N₃O₅

Purity: Min. 95%

Molecular weight: 393.39 g/mol

Ref: 3D-FF137674